|Bid||289.59 x 1000|
|Ask||289.57 x 1000|
|Day's range||289.06 - 295.03|
|52-week range||195.91 - 309.60|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||10.27|
|Earnings date||09 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||29 Mar 1994|
|1y target est||336.14|
BURLINGTON, N.C., December 03, 2021--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. The addition of Toxikon to Labcorp Drug Development bolsters Labcorp’s strong nonclinical development portfolio, and creates a strategic footprint for the company to partner with pharmaceutical and biotechnology clients in the Boston, Mass.
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
Cooper Companies' (COO) fiscal fourth-quarter results reflect solid segmental and geographical performances.